Verve Therapeutics Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	6	-	780.86	363.18	31.6
Revenue Growth (YoY)	-	-	115.01%	1049.22%	-
Cost of Revenue	6	-	704.79	332.81	19.91
Gross Profit	-	-	76.08	30.36	11.69
Selling, General & Admin	3	3	152.14	92.1	42.29
Other Operating Expenses	40	6	134.66	128.1	54.8
Operating Expenses	43	9	297.81	225.55	100.86
Operating Income	-43	-9	-221.73	-195.19	-89.16
Interest Expense	-1	-1	-0.79	-0.66	-0.68
Interest & Investment Income	186	41	18.38	3.15	0.92
Earnings From Equity Investments	-143	-	-	-	-
Currency Exchange Gain (Loss)	-	-	1.1	0.4	-
Other Non Operating Income (Expenses)	-1	-	-1.02	-0	0
Pretax Income	-2	31	-204.07	-192.3	-88.92
Income Tax Expense	13	-	-	-	-
Earnings From Continuing Operations	-15	31	-204.07	-192.3	-88.92
Earnings From Discontinued Operations	4,810	-202	-	-	-
Net Income	4,795	-171	-204.07	-192.3	-88.92
Net Income to Common	4,795	-171	-204.07	-192.3	-88.92
Shares Outstanding (Basic)	604	604	604	581	469
Shares Outstanding (Diluted)	604	604	604	581	469
Shares Change (YoY)	-	-	4.03%	23.92%	-
EPS (Basic)	7.94	-0.28	-0.34	-0.33	-0.19
EPS (Diluted)	7.94	-0.28	-0.34	-0.33	-0.19
Free Cash Flow	-154	139	-160.31	51.34	-51.84
Free Cash Flow Per Share	-0.26	0.23	-0.27	0.09	-0.11
Gross Margin	-	-	9.74%	8.36%	37.00%
Operating Margin	-716.67%	-	-28.40%	-53.74%	-282.15%
Profit Margin	79916.67%	-	-26.13%	-52.95%	-281.38%
Free Cash Flow Margin	-2566.67%	-	-20.53%	14.14%	-164.05%
EBITDA	-34	7	-219.44	-194.97	-
EBITDA Margin	-	-	-28.10%	-53.69%	-
D&A For EBITDA	9	16	2.3	0.22	-
EBIT	-43	-9	-221.73	-195.19	-89.16
EBIT Margin	-	-	-28.40%	-53.74%	-282.15%

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.